High MicroRNA-370 Expression Correlates with Tumor Progression and Poor Prognosis in Breast Cancer.
10.4048/jbc.2015.18.4.323
- Author:
Jongmin SIM
1
;
Hyein AHN
;
Rehman ABDUL
;
Hyunsung KIM
;
Ki Jong YI
;
Yu Min CHUNG
;
Min Sung CHUNG
;
Seung Sam PAIK
;
Young Soo SONG
;
Kiseok JANG
Author Information
1. Department of Pathology, Hanyang University College of Medicine, Seoul, Korea. medartisan@hanyang.ac.kr
- Publication Type:Original Article
- Keywords:
Breast neoplasms;
MicroRNA-370;
Prognosis;
Real-time polymerase chain reaction
- MeSH:
Breast Neoplasms*;
Breast*;
Disease-Free Survival;
Genes, Tumor Suppressor;
Humans;
Immunohistochemistry;
Lymph Nodes;
Neoplasm Metastasis;
Oncogenes;
Prognosis*;
Real-Time Polymerase Chain Reaction;
Up-Regulation
- From:Journal of Breast Cancer
2015;18(4):323-328
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Deregulation of microRNA-370 (miR-370) has been reported in various cancers, in which it can act as either an oncogene or a tumor suppressor gene. However, the clinicopathologic significance of miR-370 expression in breast cancer has not been studied. METHODS: The expression of miR-370 was determined with quantitative real-time polymerase chain reaction in 60 formalin-fixed, paraffin-embedded primary breast cancer tissues. Additionally, the protein expression levels of previously known targets of miR-370, such as FOXM1, FOXO1, and FOXO3a, were detected using immunohistochemistry. Finally, we analyzed its correlation with target protein expression, clinicopathologic features, and clinical outcome. RESULTS: High levels of miR-370 expression correlated with lymph node metastasis (p=0.009), advanced stage (p=0.002), and frequent perineural invasion (p=0.042). Moreover, patients with high miR-370 expression had poor disease-free survival compared with the low-expression group. However, no correlation was observed between miR-370 and its target protein expression. CONCLUSION: Our results indicate that upregulation of miR-370 in breast cancer is correlated with breast cancer progression and that it might be a potential biomarker for predicting clinical outcomes.
